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There is an urgent need for human immunodeficiency virus (HIV) vaccines that induce robust mucosal
immunity. Influenza A viruses (both H1N1 and H3N2) were engineered to express simian immunodeficiency
virus (SIV) CD8 T-cell epitopes and evaluated following administration to the respiratory tracts of 11 pigtail
macaques. Influenza virus was readily detected from respiratory tract secretions, although the infections were
asymptomatic. Animals seroconverted to influenza virus and generated CD8 and CD4 T-cell responses to
influenza virus proteins. SIV-specific CD8 T-cell responses bearing the mucosal homing marker 7 integrin
were induced by vaccination of naïve animals. Further, SIV-specific CD8 T-cell responses could be boosted by
recombinant influenza virus-SIV vaccination of animals with already-established SIV infection. Sequential
vaccination with influenza virus-SIV recombinants of different subtypes (H1N1 followed by H3N2 or vice versa)
produced only a limited boost in immunity, probably reflecting T-cell immunity to conserved internal proteins
of influenza A virus. SIV challenge of macaques vaccinated with an influenza virus expressing a single SIV CD8
T cell resulted in a large anamnestic recall CD8 T-cell response, but immune escape rapidly ensued and there
was no impact on chronic SIV viremia. Although our results suggest that influenza virus-HIV vaccines hold
promise for the induction of mucosal immunity to HIV, broader antigen cover will be needed to limit cytotoxic
T-lymphocyte escape.
Developing a safe and effective human immunodeficiency
virus (HIV) vaccine is one of the defining scientific challenges
of our time. Induction of peripheral CD8 T-cell immunity to
HIV did not protect against sexual exposure to HIV type 1
(HIV-1) in humans in a recent efficacy trial (11, 43). In simian
immunodeficiency virus (SIV)-macaque studies, peripheral
CD8 T-cell immunity can effectively control viremia (40) but is
often observed to have a transient or limited role in delaying
SIV disease in macaques (32). The gradual accumulation of
immune escape at CD8 T-cell epitopes undermines the effec-
tiveness of CD8 T-cell immunity to SIV (6, 22, 46). It is likely
that inducing mucosal CD8 T-cell immunity to HIV will be
more effective at limiting viral replication during the very early
phases of acute infection, prior to massive viral dissemination
and destruction of large numbers of CD4 T cells (50). The
induction of multifunctional mucosal CD8 T cells by live at-
tenuated SIV vaccination of macaques is thought to play a
significant role in the success of this strategy (25, 26); however,
it is unfortunately too dangerous for clinical trials at present.
A series of mucosal viral and bacterial HIV vaccine vectors
have been studied in recent years; however, none have yet
proceeded to advanced clinical trials. Live attenuated poliovi-
rus vectors have shown promise in SIV studies, but these vi-
ruses can in rare cases revert to virulence (14). Salmonella-
based SIV vaccine vectors are able to induce CD8 T-cell
responses which express the 47 integrin mucosal homing
marker when administered orally (20, 24). However, there may
be a much stronger link between concomitant genital tract
immunity and immunity induced at respiratory mucosal sites
compared to that induced at enteric sites (33, 38, 42). Vesicular
stomatitis virus vectors that replicate in the nasal mucosa show
promise in SIV-macaque trials but are potentially neurotoxic
(55). Replication-competent adenovirus vectors have looked
promising in some SHIV-macaque studies (49) but failed to
provide significant protection in a recent SIV-macaque study
(17) and could have similar issues of enhanced infection rates
as seen in the recent efficacy trials of replication-incompetent
adenovirus type 5 vectors.
A mucosal vector system that has several advantages over
existing models but that is relatively unexplored is recombinant
attenuated influenza viruses. Such viruses (i) have an existing
reverse genetics system to readily generate and manipulate
recombinant viruses (31, 34), (ii) are effective as anti-influenza
vaccines and licensed for human use (e.g., “Flumist” vaccine
[9]) with ready production capability, (iii) have robust respira-
tory mucosal replication that should facilitate genital mucosal
immunity, and (iv) can be generated with a variety of hemag-
glutinin (H) and neuraminidase (N) glycoproteins, potentially
enabling these viruses to be administered sequentially in
prime-boost combinations to limit the effect of antivector hu-
moral immunity (34). Mouse-adapted recombinant influenza
virus-HIV vectors have been studied in mice and demonstrated
significant induction of cellular immunity at mucosal sites (8,
27, 28, 44, 48). However, although several native influenza
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viruses replicate efficiently in the respiratory tracts of Asian
macaque species (10, 12, 52), no studies to date have examined
the immunogenicity or efficacy of recombinant attenuated in-
fluenza virus-SIV vectors in macaques.
MATERIALS AND METHODS
Recombinant influenza A viruses. Recombinant influenza A viruses were
generated using an eight-plasmid reverse genetics system as previously described
(4, 31, 39, 59). Briefly, DNA constructs containing all eight influenza virus
genome segments, (including the genetically manipulated NA segments) were
transfected into a coculture of 293T and Madin-Darby canine kidney (MDCK)
cells. All viral RNAs and mRNAs required for assembly and rescue of recom-
binant virus were generated through bidirectional transcription and translation
from a single template. The two mouse-adapted strains of influenza A virus used
in this study, i.e., X31 (H3N2, A/HKx31) and PR8 (H1N1, A/Puerto Rico/8/
1934), share the same six internal gene segments but differ in their expression of
HA and NA genes. The use of both strains in vaccination enables the analysis of
secondary CD8 T-cell responses in the absence of neutralizing antibody. The
Mane-A*10-restricted CD8 T-cell epitopes KP9 (SIV Gag164–172) (23), KSA10
(SIV Tat87–96), and KVA10 (SIV Tat114–123) (53) were inserted separately into
the NA stalks of the respective viruses using recombinant PCR techniques as
previously described (31) (primers and conditions are available on request).
Transfection supernatants were used to amplify virus in 10-day-old embryonated
eggs, and the presence of recombinant virus determined using a hemagglutina-
tion assay. The retention of the correctly inserted peptide epitope within the
expanded virions was confirmed by sequencing.
Macaques and SIV infections. Eleven pigtail macaques (Macaca nemestrina)
were sourced from the Australian national macaque breeding facility and were
free from simian retrovirus D and tuberculosis. All studies were approved by the
institutional animal ethics committees. All 11 macaques expressed the common
major histocompatibility complex (MHC) I allele Mane-A*10 as assessed by
sequence-specific primer PCR as previously described (51). The macaques stud-
ied are described in Table 1. Two macaques were naïve and nine macaques were
chronically infected with SIVmac251. The infected animals had been infected for
1 to 2 years, having participated in prior vaccination/challenge experiments (19,
36, 54), and were all primed with low-level SIV-specific CD8 T-cell responses.
SIV infections were performed on naïve animals by intravenous challenge with
40 50% tissue culture infective doses of SIVmac251 as previously described (7, 19,
36). There were no detectable levels of escape mutants for the Mane-A*10-
restricted KP9 Gag epitope within the SIVmac251 stock by either cloning and
sequencing or quantitative real-time reverse transcription-PCR (qRT-PCR) as
described below, consistent with the virus being derived originally from non-
pigtail macaques.
Infection of pigtail macaques with recombinant influenza virus-SIV. All re-
combinant influenza virus-SIV vaccines were administered by both intratracheal
and intranasal administration of 108 PFU influenza virus prepared in phosphate-
buffered saline to each site. Virus was atraumatically dosed in the trachea and
then in the nose with a pipette. The animals were sedated with Ketamine for all
procedures. Each virus (H1N1 or H3N2) was administered twice (day 0 and 28),
and animals were revaccinated with the alternate subtype virus (H3N2 or H1N1)
2 to 10 months later. Successful infection with the recombinant influenza virus-
SIV vaccine was monitored by analyzing influenza virus RNA in serial swabs of
the upper respiratory tract during the course of infection (60). Briefly, samples
were analyzed with an SSIII qRT-PCR one-step kit (Invitrogen) with primers
and probe targeting the matrix gene, using an ABI 7500 real-time PCR system
(Applied Biosciences). Seroconversion to influenza A virus was assessed by a
hemagglutination inhibition assay performed on serial serum samples as previ-
ously described (47). Briefly, 25 l of H1N1 virus was incubated at room tem-
perature with twofold dilutions of sera treated with RDE (Deka Seiken, Tokyo,
Japan) for 1 h. Turkey red blood cells (25 l, vol/vol) were added, left for 30 min,
and observed for hemagglutination.
Immunogenicity studies. SIV-specific CD8 T-cell responses were monitored
on fresh whole blood by tetramer staining of CD3 CD8 lymphocytes using
fluorescent Mane-A*10 tetrameric protein folded around either the KP9,
KSA10, or KVA10 SIV peptide epitope as previously described (18, 53). Expres-
sion of the mucosal homing marker 47 integrin (13) was assessed by counter-
staining tetramer-positive cells with fluorescent rat anti-human integrin 7 (BD
Pharmingen, catalog no. 551082, clone FIB504). Influenza virus-specific T cells
were assessed using an intracellular cytokine staining (ICS) assay on fresh blood
samples by stimulation with overlapping influenza virus peptides and assessment
of the specific expression of intracellular gamma interferon (IFN-) and tumor
necrosis factor alpha (TNF-) as previously described (18). Briefly, 200 l of
fresh whole blood was stimulated with a single pool of 17-mer peptides, over-
lapping by 15 amino acids, spanning either the entire nucleoprotein (NP) (98
peptides) or matrix protein (M1) (48 peptides) (both purchased from Mimo-
topes, Clayton, Australia; purity, 65%) of A/Puerto Rico/8/1934 virus for 6 h at
37°C along with costimulatory antibodies to human CD28/CD49d (BD Bio-
TABLE 1. Animals studied and influenza virus-specific T-cell epitopes identified
SIV infection status Influenza virus-SIVvaccination regimen Animal no.
SIV Gag KP9 response
(%) postvaccinationa
Influenza virus epitope(s) mappedb
CD4 CD8
Uninfected, naı¨ve Day 0, H1N1-KP9; day 28,
H1N1-KP9; day 300,
H3N2-KP9; day 328,
H3N2-KP9
1335 0.06 M191–107 NP401–423
c
2374 0.04 NP401–423
SIV infected Day 0, H1N1-KP9; day 28,
H1N1-KP9; day 98,
H3N2-KP9; day 126,
H3N2-KP9
5821 8.78 NP466–482, NP300–362
d,
M136–57, M151–112
d
NP401–423
5827 10.22 NP186–202, M136–57,
NP300–362
d, NP401–462
d
NP311–332, NP456–472, NP482–498
M141–62, M186–107
086B 3.79 NP151–212
d, NP300–362
d NP401–423, NP151–212
d
8305 0.48 NP401–423
Day 0, H3N2-KP9; day 28,
H3N2-KP9; day 77,
H1N1-KP9; day 105,
H1N1-KP9
8454e 0.74 NP300–362
d, NP186–202 NP451–498
d
9017e 0.57
9020e 0.11
1.3731e 0.47 NP451–498
d, M186–107
Day 0, H1N1-KP9, H1N1-
KSA10, H1N1-KVA10
5612 8.74 Not done Not done
a Peak CD8 T-cell response determined by KP9/Mane-A*10 tetramer, expressed as percentage of all CD8 T cells.
b Common epitopes identified are in bold.
c The NP401–423 response was mapped to minimal epitope NP402–410 (SAGQISIQP, SP9) as shown in Fig. 4B.
d Pool of 10 overlapping peptides, not finely mapped.
e Studied only for responses to epitopes already mapped in animals 5821, 5827, 086B, and 8305.
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sciences/Pharmingen, San Diego CA) and 10 g/ml brefeldin A (Sigma, St.
Louis, MO). Cells were labeled with anti-CD3–AF700 (clone SP34-2), anti-CD4–
fluorescein isothiocyanate (clone M-T477), and anti-CD8–peridinin chlorophyll
protein (clone SK1); red blood cells were lysed with BD fluorescence-activated
cell sorter lysing solution; and remaining leukocytes were permeabilized with BD
permeabilizing solution 2 and then incubated with anti-human IFN-–allophy-
cocyanin (clone B27) and anti-human TNF-–PeCy7 (clone mAb11) (all from
BD Biosciences) and fixed with 1% formaldehyde (Polysciences, Inc., War-
rington, PA). Flow cytometric data were analyzed with FloJo software version
7.2.2 and influenza virus-specific T-cell frequencies calculated as the proportion
of CD4 or CD8 T cells expressing the particular cytokine molecule. Background
expression of cytokines following dimethyl sulfoxide stimulation alone was gen-
erally 0.2% and was subtracted from antigen-specific levels. To map individual
influenza virus peptide-specific T-cell responses, pools of 10 peptides were
mapped and then individual peptides tested with fresh blood samples. A partic-
ular influenza virus NP-specific CD8 T-cell response was finely mapped by
purchasing 9- to 10-mer peptides spanning an overlapping pair of 17-mer pep-
tides and assessing cytokine expression to fresh blood incubated with peptide
dilutions.
qRT-PCR assay to detect virus escape mutant K165R. As the vaccinations
stimulated only SIV-specific CD8 T-cell responses that are known to be suscep-
tible to immune escape (23), we studied escape from KP9-specific CD8 cells in
the vaccinated/challenged animals 1335 and 2374. We utilized a qRT-PCR assay
that specifically amplifies SIV that either is wild type (WT) at KP9 or carries the
K165R mutation, which is the dominant escape mutation at this epitope as
previously described and validated (41). The assays use a forward primer specific
for either the WT sequence or the K165R KP9 escape mutant sequence. Briefly,
for each time point after SIV infection 10 l of RNA, extracted from EDTA-
anticoagulated plasma, was subjected to reverse transcription, and then cDNA
was amplified by qRT-PCR using either WT or escape mutant primers specific
for the SIV Gag KP9 epitope. A reverse primer and 5 6-carboxyfluorescein-
labeled minor groove binding DNA probe were also added for quantification
against the SIV Gag epitope RNA standards using an Eppendorf Realplex4
cycler. Baselines were set two cycles earlier than real reported fluorescence, and
the threshold value was determined by setting the threshold bar within the linear
data phase. Samples amplifying after 40 cycles were regarded as negative, cor-
responding to 1.5 log10 SHIV/SIV RNA copies/ml of plasma.
RESULTS
Influenza virus-SIV vaccination studies of macaques. To
assess the infectivity and immunogenicity of recombinant in-
fluenza virus-SIV expressing the SIV Gag KP9 epitope, we
inoculated two naïve pigtail macaques, which expressed the
Mane-A*10 allele (animals 1335 and 2374), with 108 PFU of
recombinant H1N1 influenza virus (PR8)-SIV via the respira-
tory tract twice at a 4-week interval. Swabs of the respiratory
tract were analyzed for influenza virus RNA daily. Influenza
virus RNA was recovered from both animals at multiple sites
after the first inoculation (Fig. 1A). Virus levels peaked at 1 to
2 days after inoculation and were cleared by day 7. Two days
after a second inoculation with the same virus on day 28, no
RNA was detected. This suggests both (i) an adaptive immune
response generated to the initial infection and (ii) that the
detection of influenza virus RNA after the first inoculation was
due to replicating virus and not to sampling of the inoculum.
To evaluate humoral recognition of influenza virus, we ana-
lyzed serial serum hemagglutination inhibition titers against
the homologous parent H1N1 virus and observed a uniform
seroconversion within 7 days of inoculation (Fig. 1B). The
second inoculation did not further boost antibody levels.
To determine immunogenicity against the inserted SIV
epitope, we analyzed serial fresh blood samples for the pres-
ence of KP9-specific T cells using the Mane-A*10/KP9 tet-
ramer. We observed a small but clearly detectable KP9-specific
CD8 T-cell response after the initial inoculation (Fig. 1C). This
response was marginally boosted after the second inoculation.
The minimal boosting is consistent with humoral influenza
virus immunity limiting replication of the vector.
Influenza virus-SIV vaccination of SIV-infected macaques.
To further characterize the immunogenicity of influenza virus-
FIG. 1. Vaccination of pigtail macaques with recombinant influ-
enza virus-SIV. Two naïve pigtail macaques expressing the Mane-A*10
allele were vaccinated twice with recombinant 108 PFU influenza A
virus (H1N1 influenza virus KP9, PR8 strain) 4 weeks apart. (A) Re-
covery of influenza virus RNA from respiratory swabs by qRT-PCR.
(B) Seroconversion to influenza A virus by hemagglutination inhibition
(HI). (C) Detection of SIV Gag KP9-specific CD8 T cells in blood by
KP9/Mane-A*10 tetramer staining. The proportion of all CD8 T cells
staining for the KP9/Mane-A*10 tetramer is shown.
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SIV vaccination of pigtail macaques, we conducted additional
influenza virus-SIV vaccination studies of a series of eight
Mane-A*10 SIV-infected macaques used in prior therapeutic
vaccine studies (Table 1). The macaques were infected with
SIVmac251 1 to 2 years previously and had primed KP9-specific
CD8 T-cell responses, and so they could be used to assess the
immunostimulatory capacity of recombinant influenza virus-
SIV prime-boost regimens. We studied two prime-boost regi-
mens, each with four animals, with two doses of H1N1 influ-
enza virus-SIV vaccination followed by two doses of H3N2
influenza virus-SIV vaccination or vice versa (Table 1; Fig. 2).
As with the infection of the naïve animals, influenza virus RNA
was recovered from the respiratory tracts of infected animals,
and all animals seroconverted to influenza virus (data not
shown). Both regimens were effective in reboosting KP9-spe-
cific CD8 T cells (Fig. 2). Following the H1N1-SIV prime/
H3N2-SIV boost regimen, three of the four animals (animals
5821, 5827, and 086B) had substantial expansion of KP9-spe-
cific CD8 T cells, i.e., up to 10% of all CD8 T cells after the
initial H1N1 influenza virus-SIV vaccination (Fig. 2A). These
very large responses were not substantially reboosted by sub-
sequent immunization with the H3N2-SIV virus. The four an-
imals receiving first the H3N2 influenza virus-SIV recombinant
virus had a more modest expansion of KP9-specific CD8 T cells
after the initial vaccination (to 	0.5%) (Fig. 2B), although
these cells reexpanded to similar levels after the H1N1 boost.
These studies suggest that SIV-specific CD8 T cells can be
boosted by influenza virus-SIV vaccination of SIV-infected
animals and that prime-boost immunization with heterologous
influenza virus strains can maintain high levels of SIV-specific
T cells.
Characterization of influenza virus-specific CD8 T cells.
The limited expansion of SIV-specific CD8 T cells following
boosting with a heterologous influenza virus-SIV vector sug-
gested that adaptive immune responses to influenza virus other
than antibody responses could play a role in reducing the
effectiveness of the boost. We therefore assessed serial fresh
blood samples for influenza virus-specific T-cell responses by
ICS throughout the course of the influenza virus-SIV vaccina-
tion study. To our knowledge, influenza virus-specific T-cell
immunity has not previously been analyzed in pigtail macaque
models or mapped in any macaque model. We studied re-
sponses to influenza virus NP and M1. These proteins are
conserved for both the H1N1 and H3N2 strains used for vac-
cination, and NP is a common target for CD8 T-cell immunity
in both mice and humans (57, 58). The majority of animals
vaccinated with the recombinant influenza virus-SIV generated
antiviral cytokine-producing CD8 and CD4 T cells in response
to restimulation with overlapping peptides of NP (Fig. 3).
T-cell responses to M1 protein were much smaller and less
common (not shown). NP-specific CD8 T-cell responses begin
to appear at day 35 following two doses of the initial recom-
binant influenza virus strain and were further boosted follow-
ing one dose of the alternate heterologous recombinant influ-
enza virus strain (Fig. 3A and C). A similar trend was observed
for the generation of NP-specific CD4 T cells (Fig. 3B and D).
The reasonably robust T-cell responses to the whole influ-
enza virus NP peptide pool suggested that the immune re-
sponse in these pigtail macaques could target common NP
epitopes. We therefore used smaller sets of 10 overlapping
peptides to map CD4 and CD8 T-cell epitopes of NP and M1.
The influenza virus-specific CD4 and CD8 T-cell epitopes
mapped to individual peptides are shown in Table 1. During
epitope mapping analysis of one animal (2374), peptides 80
and 81 of NP (NP401–423) stimulated a robust response CD8
T-cell response encompassing the majority of the IFN- and
TNF--producing CD8 T cells to NP (Fig. 4A).
To finely map the NP-specific CD9 T-cell epitope, we pur-
chased seven smaller peptides across this epitope and per-
formed an ICS experiment on fresh blood from animal 2374
using reducing titrations of each peptide. The minimal epitope,
being the smallest peptide that did not titrate out, was a 9-mer
(SP9, NP402–410) (Fig. 4B). Defining this macaque influenza
virus-specific CD8 T-cell epitope allowed us to screen blood
samples from other influenza virus-SIV-infected macaques. A
response to this NP epitope was common to four other vacci-
nated animals (Fig. 4A). These animals all share the MHC I
allele Mane-A*10 but not any other MHC I alleles typed for,
suggesting that the observed shared response to this influenza
virus CD8 T-cell epitope is restricted by Mane-A*10.
SIV challenge of influenza virus-SIV vaccinated macaques.
To assess the efficacy of the influenza virus-SIV vaccination,
the naïve pigtail macaques vaccinated with the influenza virus-
SIV recombinants were challenged with SIVmac251 6 weeks
FIG. 2. Prime-boost vaccination of SIV-infected macaques with
heterologous influenza virus-SIV vaccines. Groups of four Mane-A*10-
expressing pigtail macaques with chronic SIV infection were adminis-
tered either two doses of H1N1 influenza virus-KP9 SIV vaccine fol-
lowed by two doses of H3N2 influenza virus-KP9 SIV vaccine (A) or
two doses of H3N2 influenza virus-KP9 SIV vaccine followed by two
doses of H1N1 influenza virus-KP9 SIV vaccine (B). SIV Gag KP9-
specific CD8 T cells in blood were assessed by KP9/Mane-A*10 tet-
ramer staining, shown as a proportion of total CD8 T cells.
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after the final vaccination. Both animals became infected, and
acute SIV viral loads at 10 to 21 days after infection ranged
from 5.52 to 6.88 log10 copies/ml (mean of 6.62 at day 14) (Fig.
5A). This is not significantly lower than the mean (
 standard
deviation) day 14 SIV viral load of 7.07 
 0.54 log10 copies/ml
for 36 unimmunized historical control animals infected with
the same SIVmac251 stock (19). Levels of SIV viremia beyond
acute infection remained high at 5 to 6 log10 copies/ml in
influenza virus-SIV-immunized animals (mean, 5.60 log10 cop-
ies) and similar to that in historical control animals (mean 

standard deviation, 5.40 
 1.08 log10 copies/ml [36]). Consis-
tent with the high levels of continuing viremia, a gradual pe-
ripheral CD4 T-cell depletion ensued (Fig. 5B).
Recall responses to the SIV KP9 epitope were studied with
serial blood samples. After challenge with SIVmac251, a massive
boosting of KP9-specific T cells to 8 to 10% of all CD8 T cells
was observed in both macaques, demonstrating effective prim-
ing of this response (Fig. 5C).
Immune escape from SIV-specific CD8 T cells induced by
influenza virus-SIV vaccines. The high levels of viremia in the
context of a very large recall CD8 T-cell response to SIV KP9
suggest that rapid early immune escape may have undermined
the narrow SIV-specific immunity induced by vaccination. As
the vaccination stimulated only SIV-specific CD8 T-cell re-
sponses that are known to be susceptible to immune escape
(23), we studied escape from KP9-specific CD8 cells in the
vaccinated/challenged animals, 1335 and 2374. Serial plasma
samples were analyzed using a novel qRT-PCR that quantifies
both WT viremia and the dominant K165R escape mutant
viremia (41). We observed rapid early escape at the KP9
epitope in both animals (Fig. 5E). The escape mutant strain
was first detected 10 to 14 days after challenge, and the level of
the escape mutant virus exceed that of WT virus 5 weeks after
infection and dominated the viral population thereafter.
Induction of 7 integrin-expressing SIV-specific CD8 T cells
by influenza virus-SIV vaccination. The 47 integrin is a
specific mucosal homing marker on CD8 T cells. Other groups
have demonstrated its role in mucosal homing of CD8 T cells
in macaque models of SIV and other virus infections (13, 35).
As the animals were immunized with the influenza virus-SIV
recombinants via the respiratory tract, we analyzed the expres-
sion of the 7 subunit on peripheral KP9-specific CD8 T cells.
Both after vaccination and immediately after SIV challenge, 40
to 60% of KP9-specific T cells expressed the 7 surface inte-
grin molecule (Fig. 5D). Interestingly, a sharp transient decline
in 7 expression on circulating KP9-specific T cells was ob-
served at day 14, temporally associated with a dramatic in-
crease in the CD8 T-cell response after challenge.
Expanded SIV antigen coverage with influenza virus-SIV
vaccines. Vaccines that stimulate a single CD8 T-cell epitope
can provide valuable information for that population of CD8 T
cells; however, they (i) are unlikely to adequately model vac-
cines that express multiple antigens and (ii) leave the host
susceptible to immune escape (as we observed above). We
therefore constructed influenza virus-SIV recombinants ex-
pressing two additional recently described Mane-A*10-re-
stricted SIV CD8 T-cell epitopes located in the Tat protein
(KSA10 and KVA10) (53), H1N1-KSA10 and H1N1-KVA10.
FIG. 3. Influenza virus-specific T-cell immunity following influenza virus-SIV vaccination. Serial macaque fresh blood samples were assessed
for the proportion of CD4 or CD8 T cells specifically expressing both IFN- and TNF- following stimulation with a pool of overlapping peptides
spanning the influenza virus NP protein. NP-specific CD8 and CD4 T-cell responses in four animals receiving H1N1 influenza virus-KP9 SIV
followed by H3N2 influenza virus-KP9 SIV are shown in the left panels (A and B), and responses in animals receiving H3N2 influenza virus-KP9
SIV followed by H1N1 influenza virus-KP9 SIV shown in the right panels (C and D).
VOL. 83, 2009 EVALUATION OF INFLUENZA VIRUS-SIV VACCINES IN MACAQUES 7623
We immunized a Mane-A*10 SIV-infected macaque with 108
PFU of each virus simultaneously via the respiratory tract.
There was a significant boost in CD8 T cells specific for all
three SIV epitopes, particularly KP9 and KSA10 and to a
lesser extent KVA10 (Fig. 6). This provides a model for the
induction of broader SIV-specific CD8 T cells by mucosally
administered vaccination.
DISCUSSION
Improved vaccines to prevent or ameliorate HIV infection
are needed. We constructed a series of H1N1 and H3N2 re-
combinant influenza virus-SIVs and showed that these viruses
can infect pigtail macaques via the respiratory mucosa and
induce or boost SIV-specific CD8 T-cell responses. The SIV-
specific CD8 T-cell responses expressed the 47 integrin mu-
cosal homing marker and were boosted substantially after SIV
challenge. Unfortunately, the SIV-specific CD8 T cells induced
by the vaccines to a single SIV epitope rapidly selected for
immune escape viral mutants, and no protection against
chronic SIV infection was observed, illustrating that broad
immunity will be required to control such viruses. Although we
also show that it is possible to boost responses to at least three
SIV-specific CD8 T-cell responses using panels of recombinant
influenza virus-SIV recombinants, the breadth of immunity
required to adequately limit virus replication is not yet clear.
Our work with macaques on this novel mucosa-based vaccine
platform provides opportunities to probe the requirements for
effective mucosal T-cell immunity to viruses such as HIV.
Our study significantly expands on previous mouse work on
recombinant influenza virus-HIV vaccine concepts (27, 28, 44,
45, 48). Murine studies showed the potential for recombinant
influenza virus vaccines to be used in combination with other
vaccine vectors (27, 28, 44). In our macaque trials we investi-
gated sequential administration of heterologous influenza A
virus strains and showed some boosting of CD8 T cells to the
inserted SIV epitope. A potential limitation of this approach is
the induction of cross-reactive influenza virus-specific T-cell
immunity induced by the initial immunization that limits the
effectiveness of the boosting vector. Indeed, we show that in-
fluenza virus-specific CD4 and CD8 T-cell immunity was
readily induced in macaques with this immunization strategy.
Further, we identified and finely mapped a common influenza
virus NP CD8 T-cell epitope presented by multiple pigtail
macaques. This facilitates the identification and characteriza-
tion of influenza virus-specific CD8 T cells and allows future
comparative studies of the effectiveness of CD8 T cells to acute
(influenza virus) and chronic (SIV) viruses in pigtail macaques.
We studied mouse-adapted PR8 and X31 influenza A virus
strains; these attenuated strains did not cause any symptoms
and were cleared within 1 week of inoculation. Rapid clear-
ance of the vector may have resulted in more transient SIV-
specific immunity, although most vector-based vaccines, other
than persistent viruses such as retroviruses and herpesviruses
(15, 30), will be eliminated relatively quickly. The use of non-
mouse-adapted influenza A virus strains with higher replicative
capacity in primates should provide more robust and durable
immunity that may not require frequent reboosting but could
come at the cost of some symptoms or disease (12). The ef-
fectiveness of recombinant vaccines based on cold-adapted
strains such as those used in the licensed live attenuated influ-
enza virus vaccines requires further study. A key practical
advantage of recombinant influenza virus-HIV vaccines is the
ready availability of technologies, manufacturing capacity, and
marketing of existing cold-adapted live attenuated influenza
virus vaccines. Such technologies are rarely present for other
live vectors and should, when suitable vaccine candidates are
generated, substantially speed the development of this tech-
nology into clinical trials.
The ability to induce mucosal immunity is widely viewed as
essential for improved HIV vaccine efforts. Influenza virus
vectors delivered to the upper respiratory tract in mice robustly
induce genital mucosal T-cell immunity (33). Our studies of
the induction of SIV-specific CD8 T cells expressing the mu-
FIG. 4. Identification of a common influenza virus NP CD8 T-cell
epitope in pigtail macaques. Macaques responding to the pool of NP
peptides had T-cell responses to individual or overlapping influenza
virus NP peptides assessed on serial fresh blood samples. (A) Macaque
2374 had a robust CD8 T-cell response to NP, as evidenced by IFN-
and TNF- expression. The majority of NP-responding CD8 T cells
were directed to two overlapping peptides, peptides 80 and 81 (NP401–423)
of the pool of 98 overlapping NP 17-mer peptides. Three other ma-
caques responding to the whole NP pool and also responding to these
two NP peptides are also shown (lower fluorescence-activated cell
sorter plots). (B) Fine mapping of the common NP CD8 T-cell re-
sponse was performed by ICS on a series of 9- to 10-mer peptides
spanning the overlap between NP peptides 80 and 81.
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cosal homing integrin 47 suggest that similar levels of gen-
ital mucosal immunity could be induced by influenza virus-
HIV vector vaccines, although future biopsy- or autopsy-based
studies are needed to confirm the presence and function of
elevated numbers of mucosal SIV-specific T cells. The levels of
47 expression on circulating SIV-specific CD8 T cells are
similar to those observed following live attenuated SIV infec-
tion (where virus also replicates at mucosal sites) and were
comparable, if not better, than those in previous studies using
DNA or viral vector vaccines administered intramuscularly
(13, 35). Interestingly, we observed a sharp decline in periph-
eral 7 SIV-specific CD8 T cells during acute SIV infection.
One interpretation of this observation is that the 7/tet-
ramer-positive cells have left the circulation and headed to-
ward SIV-infected mucosal tissues. If we can subsequently
show that circulating 7/tetramer-positive CD8 T cells do
indeed accumulate rapidly in mucosal sites by sampling tissues
FIG. 5. Outcome of SIVmac251 challenge of influenza virus-SIV-
vaccinated macaques. Two naïve macaques vaccinated with recombi-
nant influenza virus-SIV expressing the SIV Gag KP9 epitope (H1N1-
KP9 and H3N2-KP9) were challenged intravenously with SIVmac251
and serial blood samples analyzed. (A) SIV plasma RNA. Viral load
analyses (mean 
 standard error) from 48 untreated historical pigtail
macaques controls infected with the same SIVmac251 stock from 2
previously studies are shown in gray for comparison. (B) Total periph-
eral CD4 T cells. (C) SIV Gag KP9-specific CD8 T cells. (D) Expres-
sion of the 47 integrin on KP9/Mane-A*10 tetramer-positive CD8 T
cells. (E) SIV KP9 WT and SIV KP9-K165R escape mutant (EM) virus
levels determined by qRT-PCR.
FIG. 6. Simultaneous induction of three SIV-specific CD8 T-cell
responses using influenza virus-SIV vaccines. A Mane-A*10-expressing
pigtail macaque with chronic SIV infection was simultaneously admin-
istered three H1N1 (PR8) influenza virus-SIV recombinants express-
ing either the SIV Gag KP9, SIV Tat KVA10, or SIV Tat KSA10
epitope. CD8 T-cell responses to each SIV epitope were followed by
MHC I tetramer staining of fresh blood samples. (A) SIV-specific CD8
T-cell responses determined by tetramer staining after immunization.
(B) Graph of responses over time.
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in expanded studies, this could be indicative of an effective
mucosal vaccination strategy. An alternative and more worri-
some explanation, however, could be the specific targeting of
47-expressing CD8 T cells by SIV. Recent observations
show that this integrin can bind HIV-1 and act as a facilitator
of HIV-1 dissemination (5). CD4, rather than CD8, T cells are
usually targeted by HIV/SIV infection; however, future studies
should examine the infectivity of these T-cell populations.
An “Achilles heel” of CD8 T cell-based vaccine strategies is
mutational escape (6, 29). Vaccinating with influenza virus
recombinants expressing only a single SIV CD8 T-cell epitope
(KP9, SIV Gag164-172) resulted in early, rapid, and complete
immune escape of target virus using our novel qRT-PCR assay
for the canonical K165R escape variant. Although escape may
come at a “fitness cost” to the virus, this must have less impact
on viral replication than effective CD8 T-cell immunity. The
consequence of our strategy of vaccinating only against the
KP9 epitope was a very high level of SIV-specific T cells
(	10% of all CD8 T cells) after challenge directed against a
now-mutated viral CD8 T-cell epitope. Previous studies of
rhesus macaques have elegantly shown the limitations of nar-
rowly directed SIV-specific CD8 T-cell immunity when escape
results (1–3, 6). Responses to other useful subdominant CD8
T-cell epitopes may be subverted by immunodominant “mono-
epitope” strategies (16, 22).
A broader representation of SIV-specific CD8 T-cell
epitopes, preferably supported by SIV-specific CD4 T-helper
epitopes, is clearly required to adequately control virus repli-
cation. Although we show proof of principle that at least three
SIV-specific CD8 T-cell responses (one Gag response and two
Tat responses, all presented by Mane-A*10) can be boosted
simultaneously by this recombinant influenza virus strategy, it
could be cumbersome to construct sufficient numbers of influ-
enza virus vectors to broadly cover relevant HIV/SIV T-cell
epitopes in outbred populations. Expression of whole heterol-
ogous proteins from influenza virus proteins is technically pos-
sible and has been achieved with expression of the enhanced
green fluorescence protein, interleukin-2, and tuberculosis
proteins (21, 37, 56); however, the stability of such vectors will
require careful study. We are currently constructing influenza
virus vectors expressing whole SIV proteins.
In summary, we illustrate some of the promise and potential
pitfalls of recombinant influenza virus-HIV vaccines express-
ing single SIV CD8 T-cell epitopes in macaques. Administra-
tion of these vectors to the respiratory tract reliably stimulates
SIV-specific CD8 T cells that express mucosal homing integrin
molecules. The vectors can be used in prime-boost regimens
with heterologous influenza virus strains, although the useful-
ness of this approach is limited to some degree by conserved
anti-influenza virus T-cell immunity. However, the ultimate
utility of our current influenza virus-HIV vectors as effective
vaccines requires further study, as immune escape from HIV-1
or SIV at CD8 T-cell epitopes is common. This strategy allows
us to test the breadth of induced T-cell immune responses that
will eventually be needed in future HIV vaccine strategies.
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